Authors
Latest:
Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell LymphomaTahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
Protecting privacy in the electronic era: HIPAA and HITECH mandatesIn 1890, Louise Brandeis and Samuel Warren published �¢ï¿½ï¿½The Right to Privacy�¢ï¿½ï¿½ in the Harvard Law Review, indicating private individuals were being injured by the invasions of modern-day technology
Latest:
Dr. Yoshino Discusses the Safety Profile of TAS-102Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Latest:
Dr. Zaks on Patient-Reported Symptom AssessmentsTal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, discusses patient-reported symptom assessment in the phase III JAKARTA trial of SAR302503 for myelofibrosis.
Latest:
Dr. Hilal on the Benefit of Maintenance Rituximab in Patients With MCLTalal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).
Latest:
Addressing a Crisis of Authorship AbuseTalal Hilal, MD, on the ethical principles of medical authorship and a just distribution of credit.
Latest:
Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic CancerTalia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Latest:
Promoting HPV Vaccination for Girls and BoysOncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys
Latest:
Dr. Seiwert on Managing Side Effects for Head and Neck Cancer TreatmentTanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.
Latest:
Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck CancerTanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.
Latest:
Dr. Seiwert on Pembrolizumab in Head and Neck CancerTanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.
Latest:
Dr. Seiwert on Immunotherapy in Head and Neck CancerTanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.
Latest:
Dr Jain on Baseline Differences Across Different Donor Types in MyelofibrosisTania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.
Latest:
Reducing Adverse Events Through Dose OptimizationTanios S. Bekaii-Saab, MD, discusses minimizing the toxicities associates with tyrosine kinase inhibitors (TKIs) through dose optimizations strategies, which are of particular interest at TKIs are combined with immune checkpoint inhibitors that also may impact the liver.
Latest:
Dr Bekaii-Saab on Treatment Evolutions in KRAS G12C–Mutant and HER2-Overexpressing CRCTanios Bekaii-Saab, MD, FACP, discusses the evolution of treatment for patients with KRAS G12C–mutant and HER2-overexpressing colorectal cancer.
Latest:
Audience Q&A: Best Practices in Managing HER2-Amplified CRCFielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Latest:
Exciting Treatment Opportunities in mCRCClosing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Latest:
Future Directions: Optimizing Care Through CombinationsTanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.
Latest:
Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW StudyIn his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.
Latest:
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in CareClosing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Latest:
Evolutions in the HER2-Amplified CRC Treatment LandscapeLooking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
